A Randomized Controlled Study of Propranolol for Prevention of Recurrent Gastrointestinal Bleeding in Patients with Cirrhosis: A Final Report
β Scribed by Didier Lebrec; Thierry Poynard; Jacques Bernuau; Eric Bercoff; Olivier Nouel; Jean-Pierre Capron; Raoul Poupon; Michel Bouvry; Bernard Rueff; Jean-Pierre Benhamou
- Publisher
- John Wiley and Sons
- Year
- 1984
- Tongue
- English
- Weight
- 466 KB
- Volume
- 4
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
β¦ Synopsis
We have previously reported the results of a controlled trial showing that continuous oral administration of propranolol reduced the risk of recurrent gastrointestinal bleeding in patients with cirrhosis; only part of our patients had been followed for 1 year. This controlled trial was continued for an additional year; accordingly, all of our patients have now been followed for at least 2 years. The purpose of the present study is to determine whether prolonged administration
π SIMILAR VOLUMES
To assess if propranolol prevents the first bleeding in cirrhosis, we randomly assigned 174 patients with large varices to either propranolol in doses reducing the resting heart rate by 25% (85 patients) or to a placebo (oral vitamin K, 89 patients). Sixty-nine patients had alcoholic cirrhosis, 24 p
A nocturnal increase in portal pressure and blood flow was demonstrated in patients with cirrhosis, suggesting Patients. Fourteen patients with cirrhosis (10 men and 4 women, that these hemodynamic changes may contribute to the mean age 53 { 6 years [mean { SEM]; range, 35-63 years) were triggering
In cirrhotic patients with gastrointestinal bleeding, antibiotic prophylaxis decreases the incidence of infections but most randomized trials have not shown an increase in survival. The aim of this meta-analysis was to assess the efficacy of antibiotic prophylaxis in the prevention of infections and
## Abstract ## Objective To determine whether LJP 394 delays or prevents renal flare in patients with systemic lupus erythematosus (SLE) and a history of renal disease. ## Methods In a 76βweek, doubleβblind, placeboβcontrolled study, 230 SLE patients were randomized to receive 16 weekly doses of
## Abstract ## BACKGROUND The liver is the most frequent site of recurrence after curative resection in patients with colon carcinoma. For liver metastasis, a high response rate can be achieved with hepatic arterial infusion (HAI) chemotherapy. In the current study, the authors administered 5βfluo